Sinntaxis: € 50k

Sinntaxis is developing SIN020, a repurposed investigational drug that has previously been in clinical development for another indication and can therefore enter straight in to a Phase II clinical trial.  Sinntaxis was granted € 50k from the SME Instrument HORIZON 2020, phase 1. GAEU’s team at Horizon 2020 Centre of Excellence wrote the proposal.

MORE REFERENCES

FOLLOW US